Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 172

1.

Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.

Muscatello MR, Bruno A, Pandolfo G, Micò U, Scimeca G, Romeo VM, Santoro V, Settineri S, Spina E, Zoccali RA.

J Clin Psychopharmacol. 2011 Apr;31(2):174-9. doi: 10.1097/JCP.0b013e31820e3db6.

PMID:
21346614
[PubMed - indexed for MEDLINE]
2.

Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.

Bruno A, Micò U, Pandolfo G, Mallamace D, Abenavoli E, Di Nardo F, D'Arrigo C, Spina E, Zoccali RA, Muscatello MR.

J Psychopharmacol. 2012 Nov;26(11):1456-62. doi: 10.1177/0269881111431751. Epub 2012 Feb 20.

PMID:
22351381
[PubMed - indexed for MEDLINE]
3.

Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study.

Pessina E, Albert U, Bogetto F, Maina G.

Int Clin Psychopharmacol. 2009 Sep;24(5):265-9. doi: 10.1097/YIC.0b013e32832e9b91.

PMID:
19629012
[PubMed - indexed for MEDLINE]
4.

Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.

Ak M, Bulut SD, Bozkurt A, Ozsahin A.

Adv Ther. 2011 Apr;28(4):341-8. doi: 10.1007/s12325-011-0011-7. Epub 2011 Mar 21.

PMID:
21437763
[PubMed - indexed for MEDLINE]
5.

Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder.

Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E.

J Clin Psychiatry. 2011 May;72(5):716-21. doi: 10.4088/JCP.09m05266gre. Epub 2010 Aug 10.

PMID:
20816027
[PubMed - indexed for MEDLINE]
6.

Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.

Dold M, Aigner M, Lanzenberger R, Kasper S.

Int J Neuropsychopharmacol. 2013 Apr;16(3):557-74. doi: 10.1017/S1461145712000740. Epub 2012 Aug 29. Review.

PMID:
22932229
[PubMed - indexed for MEDLINE]
7.

A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.

Diniz JB, Shavitt RG, Fossaluza V, Koran L, Pereira CA, Miguel EC.

J Clin Psychopharmacol. 2011 Dec;31(6):763-8. doi: 10.1097/JCP.0b013e3182367aee.

PMID:
22020357
[PubMed - indexed for MEDLINE]
8.

Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.

Storch EA, Goddard AW, Grant JE, De Nadai AS, Goodman WK, Mutch PJ, Medlock C, Odlaug B, McDougle CJ, Murphy TK.

J Clin Psychiatry. 2013 Jun;74(6):e527-32. doi: 10.4088/JCP.12m08278.

PMID:
23842022
[PubMed - indexed for MEDLINE]
9.

The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study.

Selvi Y, Atli A, Aydin A, Besiroglu L, Ozdemir P, Ozdemir O.

Hum Psychopharmacol. 2011 Jan;26(1):51-7.

PMID:
21308781
[PubMed - indexed for MEDLINE]
10.

Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.

Kordon A, Wahl K, Koch N, Zurowski B, Anlauf M, Vielhaber K, Kahl KG, Broocks A, Voderholzer U, Hohagen F.

J Clin Psychopharmacol. 2008 Oct;28(5):550-4. doi: 10.1097/JCP.0b013e318185e735.

PMID:
18794652
[PubMed - indexed for MEDLINE]
11.

Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial).

Sayyah M, Sayyah M, Boostani H, Ghaffari SM, Hoseini A.

Depress Anxiety. 2012 Oct;29(10):850-4. doi: 10.1002/da.21996. Epub 2012 Aug 29.

PMID:
22933237
[PubMed - indexed for MEDLINE]
12.

A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.

Denys D, de Geus F, van Megen HJ, Westenberg HG.

J Clin Psychiatry. 2004 Aug;65(8):1040-8.

PMID:
15323587
[PubMed - indexed for MEDLINE]
13.

Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.

Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR.

J Clin Psychiatry. 2005 Jun;66(6):736-43.

PMID:
15960567
[PubMed - indexed for MEDLINE]
14.

Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison.

Koran LM, McElroy SL, Davidson JR, Rasmussen SA, Hollander E, Jenike MA.

J Clin Psychopharmacol. 1996 Apr;16(2):121-9.

PMID:
8690827
[PubMed - indexed for MEDLINE]
15.

Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial.

Diniz JB, Shavitt RG, Pereira CA, Hounie AG, Pimentel I, Koran LM, Dainesi SM, Miguel EC.

J Psychopharmacol. 2010 Mar;24(3):297-307. doi: 10.1177/0269881108099423. Epub 2009 Jan 22.

PMID:
19164490
[PubMed - indexed for MEDLINE]
16.

Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.

Koran LM, Aboujaoude E, Gamel NN.

J Clin Psychiatry. 2009 Nov;70(11):1530-5. doi: 10.4088/JCP.08m04605. Epub 2009 Jun 30.

PMID:
19573497
[PubMed - indexed for MEDLINE]
17.

Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.

Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J Jr, Marcus SM, Williams MT, Weaver J, Vermes D, Van Meter PE, Rodriguez CI, Powers M, Pinto A, Imms P, Hahn CG, Campeas R.

JAMA Psychiatry. 2013 Nov;70(11):1190-9. doi: 10.1001/jamapsychiatry.2013.1932.

PMID:
24026523
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.

Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S.

J Clin Psychiatry. 2004 Apr;65(4):565-8.

PMID:
15119922
[PubMed - indexed for MEDLINE]
19.

Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.

Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L.

Am J Psychiatry. 1999 Sep;156(9):1409-16.

PMID:
10484953
[PubMed - indexed for MEDLINE]
20.

Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder.

Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R, Franklin ME, Huppert JD, Kjernisted K, Rowan V, Schmidt AB, Simpson HB, Tu X.

Am J Psychiatry. 2005 Jan;162(1):151-61.

PMID:
15625214
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk